{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:46:59Z","timestamp":1771026419352,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Doctoral Programme in Drug Research in the Doctoral School of University of Eastern Finland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejpb.2016.11.023","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T19:58:54Z","timestamp":1479844734000},"page":"85-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin"],"prefix":"10.1016","volume":"112","author":[{"given":"Rami","family":"Ojarinta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki T.","family":"Heikkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Siev\u00e4nen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2016.11.023_b0005","series-title":"Pharmacokinetic Profiling in Drug Research","first-page":"259","article-title":"Predicting the intestinal solubility of poorly soluble drugs","author":"Glomme","year":"2007"},{"key":"10.1016\/j.ejpb.2016.11.023_b0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.ejpb.2016.11.023_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2016.11.023_b0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp0600182","article-title":"A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan","volume":"3","author":"Takagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.addr.2007.05.009","article-title":"Estimating drug solubility in the gastrointestinal tract","volume":"59","author":"Dressman","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2016.11.023_b0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","article-title":"A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption","volume":"57","author":"Augustijns","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0035","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1211\/0022357055263","article-title":"The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension","volume":"57","author":"Lennernas","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.11.023_b0040","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejps.2006.04.016","article-title":"Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system","volume":"29","author":"Pouton","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jps.21903","article-title":"Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis","volume":"99","author":"Murdande","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0050","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1002\/jps.22643","article-title":"Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?","volume":"100","author":"Murdande","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","volume":"17","author":"Hancock","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2016.11.023_b0060","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2012.04.066","article-title":"Emerging trends in the stabilization of amorphous drugs","volume":"453","author":"Laitinen","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0065","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1021\/mp300104s","article-title":"A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability","volume":"9","author":"Miller","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1021\/mp200460u","article-title":"The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations","volume":"9","author":"Miller","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0075","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1021\/mp200181v","article-title":"The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0080","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous solid dispersions: utilization and challenges in drug discovery and development","volume":"104","author":"He","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0085","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0090","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/jps.20906","article-title":"Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations","volume":"96","author":"Guzman","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0095","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2015.12.009","article-title":"Recent advances in co-amorphous drug formulations","volume":"100","author":"Dengale","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2016.11.023_b0100","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"Lobmann","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0105","article-title":"Co-amorphous combination of nateglinide-metformin hydrochloride for dissolution enhancement","author":"Wairkar","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2016.11.023_b0110","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3390\/pharmaceutics6030416","article-title":"Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid, proline","volume":"6","author":"Jensen","year":"2014","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2016.11.023_b0115","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1021\/mp500107s","article-title":"Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability","volume":"11","author":"Laitinen","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0120","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs\u2013Part 1: Preparation, stability and dissolution enhancement","volume":"85","author":"Lobmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0125","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejpb.2013.03.026","article-title":"Amino acids as co-amorphous stabilizers for poorly water-soluble drugs\u2013Part 2: Molecular interactions","volume":"85","author":"Lobmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0130","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijpharm.2015.10.029","article-title":"Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying","volume":"496","author":"Fong","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0135","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1021\/mp100377m","article-title":"Excipient-mediated supersaturation stabilization in human intestinal fluids","volume":"8","author":"Bevernage","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0140","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1021\/mp400299a","article-title":"Indomethacin: new polymorphs of an old drug","volume":"10","author":"Surwase","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0145","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1208\/pt050226","article-title":"Effects of water vapor absorption on the physical and chemical stability of amorphous sodium indomethacin","volume":"5","author":"Tong","year":"2004","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2016.11.023_b0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ijpharm.2014.07.035","article-title":"Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration","volume":"473","author":"Siddiqui","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0155","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ijpharm.2014.07.030","article-title":"Influence of pH and method of crystallization on the solid physical form of indomethacin","volume":"473","author":"Dubbini","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0160","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/156720111795767924","article-title":"Use of amino acids as counterions improves the solubility of the BCS II model drug, indomethacin","volume":"8","author":"ElShaer","year":"2011","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2016.11.023_b0165","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejpb.2016.06.020","article-title":"Influence of variation in molar ratio on co-amorphous drug-amino acid systems","volume":"107","author":"Jensen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0170","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1021\/acs.molpharmaceut.5b00295","article-title":"Formation mechanism of coamorphous drug-amino acid mixtures","volume":"12","author":"Jensen","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0175","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijpharm.2010.12.019","article-title":"Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods","volume":"417","author":"Karmwar","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0180","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ejps.2011.08.010","article-title":"Investigations on the effect of different cooling rates on the stability of amorphous indomethacin","volume":"44","author":"Karmwar","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2016.11.023_b0185","unstructured":"National Center for Biotechnology Information, PubChem Compound Database; CID=3715, <https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/3715> (assessed Aug. 5, 2016)."},{"key":"10.1016\/j.ejpb.2016.11.023_b0190","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.2042-7158.2010.01023.x","article-title":"Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies","volume":"62","author":"Kleberg","year":"2010","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.11.023_b0195","series-title":"Colloids, in Martin\u2019s Physical Pharmacy and Pharmaceutical Sciences: Physical, Chemical, and Biopharmaceutical Principles in the Pharmaceutical Sciences","first-page":"469","author":"Sinko","year":"2006"},{"key":"10.1016\/j.ejpb.2016.11.023_b0200","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejpb.2015.07.011","article-title":"Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine","volume":"96","author":"Lenz","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2016.11.023_b0205","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3109\/10837450.2011.595797","article-title":"Solubility and stability of indomethacin in arginine-assisted solubilization system","volume":"18","author":"Qi","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2016.11.023_b0210","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1021\/jp401609p","article-title":"Molecular dynamics simulation of the arginine-assisted solubilization of caffeic acid: intervention in the interaction","volume":"117","author":"Hirano","year":"2013","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejpb.2016.11.023_b0215","article-title":"Preparation and characterization of spray-dried co-amorphous drug-amino acid salts","author":"Jensen","year":"2015","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2016.11.023_b0220","first-page":"452","article-title":"Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media","volume":"70","author":"Heikkinen","year":"2015","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejpb.2016.11.023_b0225","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1002\/jps.22154","article-title":"Drug supersaturation in simulated and human intestinal fluids representing different nutritional states","volume":"99","author":"Bevernage","year":"2010","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116305847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641116305847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:50:02Z","timestamp":1536227402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641116305847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":45,"alternative-id":["S0939641116305847"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.11.023","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dissolution behavior of co-amorphous amino acid-indomethacin mixtures: The ability of amino acids to stabilize the supersaturated state of indomethacin","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2016.11.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}